Trials / Completed
CompletedNCT00540553
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | |
| DRUG | GSK971086 |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-10-08
- Last updated
- 2012-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00540553. Inclusion in this directory is not an endorsement.